• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

    2/9/22 2:07:12 PM ET
    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BLI alert in real time by email
    SC 13G/A 1 tm225659d21_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.  1)*

     

    Berkeley Lights, Inc.

    (Name of Issuer)

     

    Common stock

    (Title of Class of Securities)

     

    084310101

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)
    ¨Rule 13d-1(c)
    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 084310101 13G Page 2 of 5 Pages 

     

    1. NAMES OF REPORTING PERSONS    
    ARK Investment Management LLC    
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP    
    (a)¨    
    (b)¨    
    3. SEC USE ONLY    
         
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION    
    Delaware, United States    
       
    NUMBER OF
    SHARES
    BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER    
    8,006,435      
       
    6. SHARED VOTING POWER    
    0    
       
    7. SOLE DISPOSITIVE POWER    
    8,006,435      
       
    8. SHARED DISPOSITIVE POWER    
    0    
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    
    8,006,435    
       
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    
    ¨    
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)    
    11.87%    
       
    12. TYPE OF REPORTING PERSON    
    IA    
       
               

     

     

     

    CUSIP No. 084310101 13G Page 3 of 5 Pages 

     

    Item 1(a) Name of issuer:            

     

    Berkeley Lights, Inc.

      

    Item 1(b) Address of issuer's principal executive offices:            

     

    5858 Horton Street, Suite 320,

    Emeryville, CA 94608

     

    Item 2(a) Name of person filing:            

     

    ARK Investment Management LLC

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    ARK Investment Management LLC

    3 East 28th Street, 7th Floor

    New York, NY 10016

     

    Item 2(c) Citizenship:         

     

    Delaware, United States 

     

    Item 2(d) Title of class of securities:             

     

    Common stock

     

    Item 2(e) CUSIP No.:

     

    084310101

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

    CUSIP No. 084310101 13G Page 4 of 5 Pages 

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4. Ownership          

     

    (a)          Amount beneficially owned:

     

    8,006,435

     

    (b)          Percent of class:

     

    11.87%

     

    (c)          Number of shares as to which such person has:

     

    (i)  Sole power to vote or to direct the vote:  8,006,435

     

    (ii) Shared power to vote or to direct the vote:  0

     

    (iii) Sole power to dispose or to direct the disposition of:  8,006,435

     

    (iv) Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

      

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

     

    CUSIP No. 084310101 13G Page 5 of 5 Pages 

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    The reporting persons agree that this statement is filed on behalf of each of them.

     

    Dated:    February 9, 2022

     

      ARK Investment Management LLC
         
      By: /s/ Kellen Carter
        Name:  Kellen Carter
        Title:    Chief Compliance Officer

     

     

     

    Get the next $BLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLI

    DatePrice TargetRatingAnalyst
    8/10/2022$10.00 → $5.00Equal-Weight → Underweight
    Morgan Stanley
    8/10/2022Buy → Neutral
    BTIG Research
    8/10/2022$12.00 → $8.00Overweight → Neutral
    JP Morgan
    3/2/2022Outperform
    Cowen
    2/25/2022$20.00 → $14.00Equal-Weight
    Morgan Stanley
    2/15/2022$36.00 → $20.00Equal-Weight
    Morgan Stanley
    1/6/2022$61.00 → $12.00Buy → Hold
    Stifel
    1/6/2022Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $BLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berkeley Lights downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Berkeley Lights from Equal-Weight to Underweight and set a new price target of $5.00 from $10.00 previously

      8/10/22 9:27:59 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by BTIG Research

      BTIG Research downgraded Berkeley Lights from Buy to Neutral

      8/10/22 7:24:20 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by JP Morgan with a new price target

      JP Morgan downgraded Berkeley Lights from Overweight to Neutral and set a new price target of $8.00 from $12.00 previously

      8/10/22 6:23:47 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

      PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

      3/21/23 8:02:00 AM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

      EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

      2/23/23 4:23:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Berkeley Lights Inc.

      15-12G - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/12/23 9:00:26 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form POSASR filed by Berkeley Lights Inc.

      POSASR - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/2/23 5:16:24 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 POS filed by Berkeley Lights Inc.

      S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/2/23 5:06:56 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care